Retatrutide 30mg | NeuroPept Labs

Description

Retatrutide (LY3437943) is a synthetic 39-amino acid research peptide studied as a triple receptor agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon receptors simultaneously. This triple-action receptor profile distinguishes it from single-target GLP-1 agonists and dual-target compounds such as tirzepatide, making it one of the most studied metabolic research peptides in preclinical and clinical investigation.

NeuroPept Labs supplies Retatrutide 30mg as a research-grade lyophilized peptide intended strictly for in vitro laboratory and analytical research use. All batches are manufactured under controlled synthesis conditions and verified through third-party analytical testing. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code found in the product images.

Mechanism of Action (Research Overview)

Retatrutide exhibits agonist activity at three distinct receptor pathways:

• GLP-1 Receptor (GLP-1R) — class B G protein-coupled receptor; agonist binding elevates intracellular cAMP and potentiates glucose-dependent insulin secretion in pancreatic islet and beta-cell models.
• GIP Receptor (GIPR) — incretin receptor coupled to Gs signalling; studied alongside GLP-1R to characterise combined incretin receptor pharmacology in cell-based assays.
• Glucagon Receptor (GCGR) — the third target distinguishing tri-agonists from dual agonists; a hepatocyte-expressed receptor studied in models of hepatic substrate and lipid handling.

This combination is referred to in the research literature as “Triple G” receptor agonism. Receptor binding affinities and functional potency data are reported in the peer-reviewed sources cited below.

Research Significance

Retatrutide is an investigational compound. It is not approved by the FDA or any other regulatory authority for any use, and NeuroPept Labs supplies it solely as a reference compound for laboratory research — it is not the clinical trial product. Published areas of laboratory investigation include:

• Incretin and glucagon receptor signalling and cross-talk
• Receptor binding affinity, selectivity, and functional potency assays
• Hepatocyte and adipocyte lipid-handling models in vitro
• Peptide structure–activity relationship studies
• Analytical method development and reference-standard characterisation

Retatrutide 30mg Product Specifications

Available Vial Sizes and Pricing

Retatrutide is supplied by NeuroPept Labs in three vial sizes. All are the same research-grade peptide at >99% HPLC purity with batch-specific COA documentation; only the quantity of lyophilized material differs.

Storage and Handling

• Store lyophilized peptide at -20°C or below prior to reconstitution
• Avoid repeated freeze-thaw cycles to preserve structural integrity
• Protect from direct light, humidity, and room temperature exposure
• Reconstitute using appropriate sterile laboratory solvents under aseptic conditions
• Once reconstituted, store at 4°C and use within recommended research timeframes

Frequently Asked Questions

What is Retatrutide?

Retatrutide (LY3437943) is a synthetic 39-amino acid research peptide and triple receptor agonist targeting the GLP-1, GIP, and glucagon receptors. It is studied in vitro for incretin and glucagon receptor signalling, receptor selectivity, and peptide pharmacology.

How is Retatrutide different from semaglutide or tirzepatide?

Semaglutide is a single GLP-1R agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor agonism as a third target, engaging hepatic GCGR signalling not addressed by the other two receptor profiles.

Is Retatrutide approved for human use?

No. Retatrutide is an investigational compound and is not approved by the FDA or any other regulatory authority for human or veterinary use. The material supplied by NeuroPept Labs is a research-use-only reference compound for in vitro laboratory work and is not the clinical trial product.

Where can I buy Retatrutide 30mg research peptide?

Retatrutide 30mg is supplied directly by NeuroPept Labs at neuropeptlabs.com for in vitro laboratory research use. Every vial ships with batch-specific Certificate of Analysis documentation, and material is supplied to qualified researchers and institutions only.

What is the difference between the 10mg, 20mg, and 30mg vials?

All three vials contain the same research-grade Retatrutide peptide at >99% HPLC purity with batch COA documentation. They differ only in the quantity of lyophilized material supplied per vial, allowing the vial size to be matched to the scale of the in vitro protocol.

What purity is NeuroPept Labs’ Retatrutide 30mg?

Our Retatrutide 30mg research peptide is supplied at >99% purity, verified by HPLC and third-party analytical testing. COA documentation is available for every batch and can be verified at freedomdiagnosticstesting.com.

How do I verify the Certificate of Analysis?

Each batch is tested by an independent third-party laboratory. COA validity can be confirmed at freedomdiagnosticstesting.com using the Accession Number, Client ID, or Search Code shown in the product images.

How should Retatrutide 30mg be stored?

Store the lyophilized peptide at -20°C or below, away from direct light and moisture. Avoid repeated freeze-thaw cycles. Once reconstituted, store at 4°C and use within recommended laboratory timeframes.

Scientific References

1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial, NEJM 2023
2. Efficacy and Safety of Retatrutide — PMC / NIH 2025
3. Triple Agonism Based Therapies for Obesity — PMC / NIH 2025
4. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction — PMC 2024
5. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist — ScienceDirect / The Lancet

Additional information